Identification of new asthma targets
Pieris Pharmaceuticals is cooperating with the University of
Pittsburgh
December 2019
Pieris Pharmaceuticals, Inc., announced a research collaboration between the Company and two labs of the University of Pittsburgh on November 15. Pieris, a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, will join forces with Professors Sally Wenzel, MD, and Anuradha Ray, PhD, to focus on comprehensive immune phenotyping of severe asthmatic patients. Key objectives of the multi-year collaboration include patient stratification strategies for more streamlined development of therapeutic interventions as well as identifying and validating novel asthma targets.
© Pieris
The Lungs
© Pieris
Stephen S. Yoder, CEO, Pieris Pharmaceuticals Inc.
“Wenzel and Ray have been invaluable advisors to Pieris over the last several years, and I am pleased that we can strengthen our relationship with this collaborative research component in our commitment to expand our pipeline of proprietary respiratory therapeutics,” said Stephen S. Yoder, President and Chief Executive Officer of Pieris. “Emerging research from their labs demonstrates the power of combining bench-to-bedside research with big data mining, to better understand how to address the as of yet unmet needs of severe asthma patients.”
